Boston Scientific Corp (BSX) · Oct 28, 2026 · Earnings

Boston Scientific earnings beat, but 2026 guidance takes a hit

Beat — Adjusted EPS $0.73 vs ~$0.72 consensus; revenue $5.138B vs ~$5.06B consensus

Boston Scientific earnings modestly beat Q3 expectations, but its guidance cut points to a tougher recovery after the cyber incident.

Boston Scientific is a large medical-device maker trying to extend its growth through cardiovascular innovation, new product launches and an expanding pipeline while repairing operations after the August 2026 cybersecurity disruption. Operations were reported restored in September, but the incident was already expected to weigh on the second half.

MetricQ3 2026ComparisonRead
Revenue$5.138B~$5.06B consensusBeat
Adjusted EPS$0.73~$0.72 consensusBeat
Organic sales growth1.5%7.0% in Q2 2026Sharp slowdown
Q4 organic sales guidance(3.0)% to (1.0)%Prior Q3 guidance: 3.0% to 5.0%Cut
FY 2026 organic sales guidance~3.75%Prior: 5.0% to 6.0%Cut
FY 2026 adjusted EPS guidance$3.16–$3.18Prior: $3.28–$3.32Cut

The quarter narrowly beat lowered expectations, but the underlying growth engine slowed materially. Revenue of $5.138 billion rose just 1.5% organically, while adjusted EPS was $0.73 versus the published consensus of roughly $0.72 and revenue consensus of roughly $5.06 billion. The beat is real, but small; it does not offset the fact that organic growth fell sharply from the 7% pace reported in the second quarter. 〔0〕

The guidance cut is the more important signal. Management now expects fourth-quarter sales to decline 1% to 3% and reduced full-year organic growth guidance to approximately 3.75%, from the previous 5% to 6% range. Full-year adjusted EPS guidance fell to $3.16–$3.18 from $3.28–$3.32. That is a substantial reset to the recovery story, even though the cyber disruption was already known. 〔1〕

The weakness is concentrated in several operating lines, not just accounting noise. Urology declined 3.1% organically and Endoscopy declined 0.6%, while Cardiovascular grew only 1.9%; Neuromodulation was the standout at 13.0%. Meanwhile, GAAP operating income fell to $828 million from $1.048 billion, with litigation, restructuring and impairment charges adding pressure.

The innovation pipeline remains active, but it is not yet repairing the near-term demand hole. The filing highlights new trial enrollment, FDA clearances and an AI collaboration with Heartflow, which support the long-term portfolio strategy. But those developments are future growth options; the immediate business story is that the cyber-related disruption and broader segment softness have pushed the company into a negative fourth-quarter outlook.

Bottom line: Boston Scientific beat a lowered Q3 bar, but the material guidance cuts make this a mixed earnings release. The filing says the operational recovery is not yet translating into the growth or earnings trajectory investors previously expected.

What to watch next

Q4 report, late January 2027

Original filing on SEC EDGAR

More Boston Scientific Corp news

Boston Scientific earnings beat, but 2026 guidance takes a hit | BSX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.